Patents
Patents for C07K 14 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof (291,526)
04/2006
04/25/2006US7033767 Genes regulating programmed cell death
04/25/2006US7033759 Allelic opiate membrane protein for determining susceptibility of individuals to addictive diseases; monitoring response to analgesics and learning enhancement agents
04/25/2006US7033755 Diagnostics and therapeutics for glaucoma
04/25/2006US7033752 Spinal muscular atrophy diagnostic methods
04/25/2006US7033751 Comprises viral glycoprotein fusion with glutathione s-tranferase (GST) or thioredoxin for use as diagnostic tool in screening blood products for retroviral infection
04/25/2006US7033750 Recombinant P53 adenovirus methods and compositions
04/25/2006US7033749 Detection of preferential nucleotidse sequences; obtain sample, incubate with probe, detect signal, recover nucleotide sequences
04/25/2006US7033613 Serine substituted gold inserted apoferritin; transport proteins; for use in producing semiconductors
04/25/2006US7033610 Basic cell growth stimulating factors from a mammal milk product having basic to neutral isoelectric points, enriched with proliferation stimulant of rat myoblasts; wound healing agents for gastrointestinal injuries and skin
04/25/2006US7033596 Transformant for screening of inhibitors for human immunodeficiency virus
04/25/2006US7033593 Immunogen comprising an HIV envelope protein, a ligand and H2 peptide
04/25/2006US7033592 Useful in vaccines, and monoclonal antibodies against said immunogenic surface proteins; hybridoma cell line that produes said antibodies; use in diagnostic kits for determining presence, onset, or decrease in Leptospiral infection
04/25/2006US7033591 use of a membrane fraction of gram-negative bacteria such as Klebsiella pnemoniae comprising proteoglycans in combination with anticancer treatment for immunostimulant and/or inducing an antitumor immune response in mammals including humans
04/25/2006US7033585 Immunologically privileged cells and uses thereof
04/25/2006US7033572 Non-antigenic toxin-conjugate and fusion protein of internalizing receptor system
04/25/2006CA2391879C Modulation of plant response to abscisic acid
04/25/2006CA2288429C Pegylation of polypeptides
04/25/2006CA2236912C Vectors and methods for gene transfer to cells
04/22/2006CA2481452A1 Novel purified polypeptides from streptococcus pneumoniae
04/20/2006WO2006042027A2 Immunogenic and therapeutic compositions for streptococcus pyogenes
04/20/2006WO2006041906A2 Methods and compositions for immunizing against pseudomonas infection
04/20/2006WO2006041280A1 Novel regulation protein
04/20/2006WO2006040660A2 Plasmids coding for p185neu protein sequence variants and therapeutic uses thereof
04/20/2006WO2006040574A2 Lipocalin protein
04/20/2006WO2006040463A1 Porcine mast cell lines that produce heparin-type molecules
04/20/2006WO2006040357A2 Molecular targets and compounds, and methods to identify the same, useful in the treatment of joint degenerative and inflammatory diseases
04/20/2006WO2006040312A2 Fungal transcriptional activators useful in methods for producing a polypeptide
04/20/2006WO2006040157A1 Anti-angiogenic peptide
04/20/2006WO2006040129A2 Ubiquitin or gamma-crystalline conjugates for use in therapy, diagnosis and chromatography
04/20/2006WO2006040047A2 Diagnostics and therapeutics for diseases associated with rho/rac-interacting citron kinase (cit)
04/20/2006WO2005120588A3 Peptides delivered to cell nuclei
04/20/2006WO2005113802A3 Genotoxic testing
04/20/2006WO2005105841A3 Human g-protein chemokine receptor (ccr5) hdgnr10
04/20/2006WO2005097824A3 Cytokinin oxidase sequences and methods of use
04/20/2006WO2005094256A3 Polypeptides toxic to nematodes, and methods of use
04/20/2006WO2005089315A3 Methods and compositions related to skcg-1, a tumor suppressor gene
04/20/2006WO2005085867A3 Screening method for emulators of neural activity and digestive system using gpr35
04/20/2006WO2005085453A3 Seeds
04/20/2006WO2005066344A3 New plasmids, their derivatives and fragments, their methods of manufacture and application
04/20/2006WO2005060625A3 Grp receptor-related methods for treating and preventing fear-related disorders
04/20/2006WO2005059147A3 Plants having modified growth characteristics and method for making the same
04/20/2006WO2005047314A3 Fgf-beta binding and supported peptides
04/20/2006WO2004071420A3 Compositions and methods for less immunogenic protein formulations
04/20/2006WO2004065577A3 Polynucleotides and polypeptides associated with the nf-kb pathway
04/20/2006WO2004051222A3 Methods for the identification of agents for the treatment of seizures, neurological diseases, endocrinopathies and hormonal diseases
04/20/2006WO2004044164A3 Method for identifying risk of melanoma and treatments thereof
04/20/2006WO2004044011A3 Combinatorial libraries of monomer domains
04/20/2006WO2003104401A3 Cancer-linked gene as target for chemotherapy
04/20/2006US20060085870 Plant fungicide, pesticides, insecticides; insertion protease detectors; corn
04/20/2006US20060085865 Transgenic mice containing GPCR-like gene disruptions
04/20/2006US20060084799 Human cDNA clones comprising polynucleotides encoding polypeptides and methods of their use
04/20/2006US20060084798 Members of the basic helix-loop-helix-PAS (bHLH-PAS)superfamily of transcription regulators; alpha -class hypoxia-inducible factors; circadian rhythm disorders; binding partners for circadian responsive factors; transcription stimulation of genes having an E-box transcription control element
04/20/2006US20060084797 High affinity TGFbeta nucleic acid ligands and inhibitors
04/20/2006US20060084796 Sequence-determined DNA encoding methyltransferases
04/20/2006US20060084794 Albumin fusion proteins
04/20/2006US20060084793 G-CSF polypeptides and conjugates
04/20/2006US20060084792 Versatile platform for nanotechnology based on circular permutations of chaperonin protein
04/20/2006US20060084791 Purified polypeptide, isolated nucleic acids encoding said polypeptide, vectors and use thereof
04/20/2006US20060084790 P-Rex1, a ptdins (3,4,5) p3-g-beta-gamma-regulated guanine-nucleotide exchange factor for rac
04/20/2006US20060084789 Immunotherapeutic and immunoprphylactic reagents
04/20/2006US20060084623 DNA vaccination for treatment of multiple sclerosis and insulin-dependent diabetes mellitus
04/20/2006US20060084619 mesencephalic astrocyte-derived neurotrophic factor polypeptide; shown to protect the survival of embryonic mesencephalic dopaminergic neurons in culture
04/20/2006US20060084618 Adiponectin promoter and use thereof
04/20/2006US20060084611 Apoptotic compounds
04/20/2006US20060084609 Synthetic HLA binding WT-1 peptide analogues and uses thereof
04/20/2006US20060084608 Binding polypeptides and methods based thereon
04/20/2006US20060084600 Human homologues of fused gene
04/20/2006US20060084599 Compositions, methods and kits relating to notch signaling
04/20/2006US20060084597 Use of compounds having gip activity for the treatment of disorders associated with abnormal loss of cells and/or for the treatment of obesity
04/20/2006US20060084596 Administering a biodrug comprising a growth factor binding compounds having a central non-peptide organic scaffold, such as a calix[4]arene, to which arelinked cyclic tetrapeptides; angiogenesis inhibiters; antitumor agents; solid tumors;anticarciogenic agents; restenosis
04/20/2006US20060084595 Complex comprising OCIF and polysaccharide
04/20/2006US20060084593 Anti-hiv composition, production method thereof and medicament
04/20/2006US20060084164 Bacteria, yeasts or filamentous fungi, producing a fusion protein containing a hydrophobin fused to a protein, an enzyme or part of an enzyme with enzymatic activity, wherein said hydrophobin or hydrophobin-like protein has an ability to partition in aqueous two-phase systems (ATPS)
04/20/2006US20060084152 Corynebacterium glutamicum genes encoding metabolic pathway proteins
04/20/2006US20060084148 April-a novel protein with growth effects
04/20/2006US20060084147 Apo-2 receptor
04/20/2006US20060084145 sRAGE mimetibody, compositions, methods and uses
04/20/2006US20060084144 Genetic engineering; oligonucleotide detector; identification and isolation of novel DNA; transmembrane domain-deleted or transmembrane domain-inactivated protein; soluble extracellular domains; PRO polypeptide
04/20/2006US20060084143 Screen for agonists and antagonists; treat solid tumors, vascular deficiencies; polypeptide, polynucleotide, plasmid; chemotherapeutic agents, alkylating agents, antimetabolites, vinca alkaloids, plant extracts, nitrosoureas, topoisomerase inhibitors, platinum analogs, adrenocortical suppressants
04/20/2006US20060084142 tyrosine kinase; screening for inhibitors of PDGFRA; gastrointestinal stromal tumor (GIST)
04/20/2006US20060084140 Polynucleotide encoding a novel human G-protein coupled receptor, HGPRBMY39
04/20/2006US20060084139 Genetic engineering; oligonucleotide detector; identification and isolation of novel DNA; transmembrane domain-deleted or transmembrane domain-inactivated protein; soluble extracellular domains; PRO polypeptide
04/20/2006US20060084138 Genetic engineering; oligonucleotide detector; identification and isolation of novel DNA; transmembrane domain-deleted or transmembrane domain-inactivated protein; soluble extracellular domains; PRO polypeptide
04/20/2006US20060084121 OX2 receptor homologs
04/20/2006US20060084119 Preparing budding virus expressing mammalian transporter having transporter activity by culturing host cell infected with budding virus comprising gene encoding transporter and is recombinantly expressing transporter, expressing transporter on envelope of budding virus released from host cell, harvesting
04/20/2006US20060084118 Lymphocytes; transcription factors; interferons; diagnosis of autoimmune disease such as lupus
04/20/2006US20060084117 Galphaq protein variants and their use in the analysis and discovery of agonists and antagonists of chemosensory receptors
04/20/2006US20060084112 Utilization of mass spectrometry to elucidate particular biopolymer markers indicative or predictive of a particular disease state, and most particularly to specific biopolymer markers whose up-regulation, down-regulation, or relative presence in disease vs. normal states
04/20/2006US20060084108 Using myelocytomatosis viral oncogene (c-myc)replication origin polynucleotide sequences as tools in identifying modulators of cell proliferative disorders; anticarcinogenic agents
04/20/2006US20060084107 Methods of treating skin conditions using inhibitors of the CD2/LFA-3 interaction
04/20/2006US20060084102 Methods for determining precise HERG interactions by mutagenesis
04/20/2006US20060084091 Methods and compositions for polypeptide engineering
04/20/2006US20060084087 Using presence of myofibrillogenesis regulator 1 (MR-1) gene as diagnostic tool in detection of paroxysmal dystonic choreoathetosis
04/20/2006US20060084086 Proteins, polynucleotides encoding them and methods of using the same
04/20/2006US20060084084 Secreted and transmembrane polypeptides and nucleic acids encoding the same
04/20/2006US20060084073 Nucleic acids encoding human TBC-1 protein and polymorphic markers thereof
04/20/2006US20060084063 Rabs as modifiers of the p53 pathway and methods of use
04/20/2006US20060084055 Compositions and methods for the detection diagnosis and therapy of hematological malignancies
04/20/2006US20060083756 Immunogens; replication-defective; antibodies; host cells; kits
04/20/2006US20060083755 Vaccine for feline infectious peritonitis